Skip to content

Research & Evidence

  • Check icon (4)
    Significant improvements in waist circumference, eating behavior, and quality of life
  • Check icon (4)
    Up to 5x more effective for weight loss compared to standard follow-up methods
  • Check icon (4)
    More likely to succeed: patients reduced BMI category (up to 5×) and improved well-being (up to 9×)

Combining science and practical usage

Our DTx is grounded in rigorous behavioral science (CBT), nutritional science, and exercise physiology. We bridge the gap between clinical research and real-world application, ensuring that every feature in Lifeness DTx is backed by peer-reviewed evidence and validated through randomized controlled trials.

Our multidisciplinary approach combines the latest advances in digital health technology with time-tested therapeutic interventions, creating a comprehensive treatment platform that delivers measurable, sustainable results for patients with obesity and related metabolic conditions.

Current publications and studies

Published "Smart Nutrition" Study

Digital therapy was evaluated in a 12-week randomized clinical trial in primary care among people with overweight or obesity. Wellapy group showed reduced waist measures, improved eating behavior, and increased quality of life, demonstrating meaningful clinical improvements.
Show study
Frontier-Smart Nutrition

Published "Smart Nutrition" Study

Digital therapy was evaluated in a 12-week randomized clinical trial in primary care among people with overweight or obesity. Wellapy group showed reduced waist measures, improved eating behavior, and increased quality of life, demonstrating meaningful clinical improvements.
Show study

Digital therapy compared with standard follow-up in a 6-month study

In this 6-month retrospective study, Wellapy (formerly Lifeness) was compared with standard follow-up. The intervention group achieved −10% average weight loss vs. −2% in the control group. Additionally, 100% would recommend Wellapy and preferred it as a follow-up tool; 85% reported a direct positive impact on weight, 88% on motivation, 86% on treatment improvement, and 88% found it easy to use.
Show study
Image Section (5)

Digital therapy compared with standard follow-up in a 6-month study

In this 6-month retrospective study, Wellapy (formerly Lifeness) was compared with standard follow-up. The intervention group achieved −10% average weight loss vs. −2% in the control group. Additionally, 100% would recommend Wellapy and preferred it as a follow-up tool; 85% reported a direct positive impact on weight, 88% on motivation, 86% on treatment improvement, and 88% found it easy to use.
Show study

Ongoing Randomized Controlled Trial "MOOSE" (interim results)

MOOSE is a single-blinded randomized trial including adults with class I–II obesity (stratified by BMI and sex). 100 patients were analyzed at 12 weeks: participants in the Wellapy group were nearly 5× more likely to reduce BMI category and showed greater psychological quality-of-life improvements (16.7% vs. 2.1%).
Show study
Image Section (6)

Ongoing Randomized Controlled Trial "MOOSE" (interim results)

MOOSE is a single-blinded randomized trial including adults with class I–II obesity (stratified by BMI and sex). 100 patients were analyzed at 12 weeks: participants in the Wellapy group were nearly 5× more likely to reduce BMI category and showed greater psychological quality-of-life improvements (16.7% vs. 2.1%).
Show study

Cooperating scientists

Doctor black Male-1
Dr. Prof. Peter Laurent
"This app completely changed how we can treat patients with eating disorders!"
solvor@lifeness.io
White young doctor. normal outfit-1
Dr. Prof. Jennifer Lenn
"This app completely changed how we can treat patients with eating disorders!"
solvor@lifeness.io
Doctor woman
Dr. Sara Hatfeather
"This app completely changed how we can treat patients with eating disorders!"
solvor@lifeness.io
marketing manager female
Dr. Prof. Amélie Laurent
"This app completely changed how we can treat patients with eating disorders!"
solvor@lifeness.io
marketing manager female
Dr. Prof. Amélie Laurent
"This app completely changed how we can treat patients with eating disorders!"
solvor@lifeness.io
Doctor woman
Dr. Sara Hatfeather
"This app completely changed how we can treat patients with eating disorders!"
solvor@lifeness.io
White young doctor. normal outfit-1
Dr. Prof. Jennifer Lenn
"This app completely changed how we can treat patients with eating disorders!"
solvor@lifeness.io
Doctor black Male-1
Dr. Prof. Peter Laurent
"This app completely changed how we can treat patients with eating disorders!"
solvor@lifeness.io

You want to cooperate?

Arrange Appointment now

Research institutions

UIT
The Arctic University of Norway
UiT The Arctic University of Norway is a medium-sized research university that contributes to knowledge-based development at the regional, national and international level.
Visit Website
NTNU
Norwegian University of Science
NTNU is an international oriented university with headquarters in Trondheim and campuses in Gjøvik and Ålesund.
Visit Website
Sacura
Sacura
Sacura GmbH is a specialized Contract Research Organization (CRO). Sacura supports pharmaceutical and medical device companies throughout all phases of clinical research in Germany and through Europe.
Visit Website

You want to cooperate?

Arrange appointment now

Frequently asked questions

Contact us
Is using AppThera paid?
 plus minus
Wellapy is suitable for the following patients
  • who have been diagnosed with obesity (ICD-10: E66.00, E66.01)
  • who are 18 years or olderIndicationIndication
  • who have a body mass index bet
  • who do not yet have any advanced concomitant diseases
  • who are accompanied by a doctor or healthcare professional
  • who are physically and mentally capable of carrying out obesity treatment independently
  • who can speak and write German fluently
  • who have a smartphone with iOS version 13 or higher or Android version 5 or higher and are experienced
How can I track my patients' adherence? 
 plus minus
Wellapy is suitable for the following patients
  • who have been diagnosed with obesity (ICD-10: E66.00, E66.01)
  • who are 18 years or olderIndicationIndication
  • who have a body mass index bet
  • who do not yet have any advanced concomitant diseases
  • who are accompanied by a doctor or healthcare professional
  • who are physically and mentally capable of carrying out obesity treatment independently
  • who can speak and write German fluently
  • who have a smartphone with iOS version 13 or higher or Android version 5 or higher and are experienced
What efficacy evidence can I present?
 plus minus
Wellapy is suitable for the following patients
  • who have been diagnosed with obesity (ICD-10: E66.00, E66.01)
  • who are 18 years or olderIndicationIndication
  • who have a body mass index bet
  • who do not yet have any advanced concomitant diseases
  • who are accompanied by a doctor or healthcare professional
  • who are physically and mentally capable of carrying out obesity treatment independently
  • who can speak and write German fluently
  • who have a smartphone with iOS version 13 or higher or Android version 5 or higher and are experienced